Are sigma modulators an effective opportunity for cancer treatment? A patent overview (1996-2016)

References

• Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16–27.
   PubMed Web of Science ®Google Scholar
• Tripodo G, Mandracchia D, Collina S, et al. New perspectives in cancer therapy: the biotin-antitumor molecule conjugates. Med Chem. 2014;S1:1–8.
   Google Scholar
• Chimento A, Sala M, Gomez-Monterrey IM, et al. Biological activity of 3-chloro-azetidin-2-one derivatives having interesting antiproliferative activity on human breast cancer cell lines. Bioorg Med Chem Lett. 2013;23:6401–6405.
   PubMed Web of Science ®Google Scholar
• Saturnino C, Buonerba M, Boatto G, et al. Synthesis and preliminary biological evaluation of a new pyridocarbazole derivative covalently linked to a thymidine nucleoside as a potential targeted antitumoral agent. I Chem Pharm Bullettin. 2003;51:971–974.
   PubMed Web of Science ®Google Scholar
• Timmers L, Boons CC, Kropff F, et al. Adherence and patients’ experiences with the use of oral anticancer agents. Acta Oncol. 2014;53:259–267.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity: curr. Opin Neurol. 2015;28:500–507.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Huang M, Shen A, Ding J, et al. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci. 2014;35:41–50.
   PubMed Web of Science ®Google Scholar
• Martin WR, Eades CG, Thompson JA, et al. Effects of morphine-like and nalorphine-like drugs in nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976;197:517–532.
   PubMed Web of Science ®Google Scholar
• Su TP. Evidence for sigma opioid receptor: binding of [3h]skf- 10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther. 1982;223:284–290.
   PubMed Web of Science ®Google Scholar
• Maurice T, Lockhart BP. Neuroprotective and anti-amnesic potentials of sigma (sigma) receptor ligands. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21:69–102.
   PubMed Web of Science ®Google Scholar
• Vaupel DB. Naltrexone fails to antagonize the sigma effects of PCP and SKF 10,047 in the dog. Eur J Pharmacol. 1983;92:269–274.
   PubMed Web of Science ®Google Scholar
• Quirion R, Chicheportiche R, Contreras PC, et al. Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci. 1987;10:444–446.
   Web of Science ®Google Scholar
• Skuza G. Potential antidepressant activity of sigma ligands. Pol J Pharmacol. 2003;55:923–934.
   PubMedGoogle Scholar
• Hanner M, Moebius FF, Flandorfer A, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci. 1996;93:8072–8077.
   PubMed Web of Science ®Google Scholar
• Rui M, Rossi D, Marra A, et al. Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel sigma receptor (SR) modulators, as potential anticancer-agents. Eur J Med Chem. 2016;124:649–665.
   PubMed Web of Science ®Google Scholar
• Collina S, Gaggeri R, Marra A, et al. Sigma receptor modulators: a patent review. Expert Opin Ther Pat. 2013;23:597–613.
   PubMed Web of Science ®Google Scholar
• Spruce BA, Campbell LA, McTavish N, et al. Small molecule antagonists of the σ-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004;64:4875–4886.
   PubMed Web of Science ®Google Scholar
• Cassano G, Gasparre G, Niso M, et al. F281, synthetic agonist of the sigma-2 receptor, induces Ca2+ efflux from the endoplasmic reticulum and mitochondria in SK-N-SH cells. Cell Calcium. 2009;45:340–345.
   PubMed Web of Science ®Google Scholar
• Aydar E, Palmer CP, Djamgoz MB. Sigma receptors and cancer: possible involvement of ion channels. Cancer Res. 2004;64:5029–5035.
   PubMed Web of Science ®Google Scholar
• Aydar E, Onganer P, Perrett R, et al. The expression and functional characterization of sigma (σ) 1 receptors in breast cancer cell lines. Cancer Lett. 2006;242:245–257.
   PubMed Web of Science ®Google Scholar
• Wang B, Rouzier R, Albarracin CT, et al. Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res Treat. 2004;87:205–214.
   PubMed Web of Science ®Google Scholar
• Su TP, Hayashi T, Maurice T, et al. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci. 2010;31:557–566.
   PubMed Web of Science ®Google Scholar
• Marchi S, Giorgi C, Oparka M, et al. Oncogenic and oncosuppressive signal transduction at mitochondria-associated endoplasmic reticulum membranes. Mol Cell Oncol. 2014;1:e956469.
   Google Scholar
• Su TP, Su TC, Nakamura Y, et al. The sigma-1 receptor as a pluripotent modulator in living systems. Trends Pharmacol Sci. 2016;37:262–278.
   PubMed Web of Science ®Google Scholar
• Wheeler KT, Wang LM, Wallen CA, et al. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer. 2000;82:1223–1232.
   PubMed Web of Science ®Google Scholar
• Zeng C, Rothfuss J, Zhang J, et al. Sigma-2 ligands induce tumour cell death by multiple signalling pathways. Br J Cancer. 2012;106:693–701.
   PubMed Web of Science ®Google Scholar
• Zeng C, Vangveravong S, Xu J, et al. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res. 2007;67:6708–6716.
   PubMed Web of Science ®Google Scholar
• Huang YS, Lu HL, Zhang LJ, et al. Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy: sigma-2 receptor ligands. Med Res Rev. 2014;34:532–566.
   PubMed Web of Science ®Google Scholar
• Abate C, Niso M, Marottoli R, et al. Novel derivatives of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with improved fluorescent and σ receptors binding properties. J Med Chem. 2014;57:3314–3323.
   PubMed Web of Science ®Google Scholar
• Australian Nuclear Science & Technology Organisation. Piperidine-based sigma receptor ligands. WO9620928; 1996
   Google Scholar
• Gilligan PJ, Cain GA, Christos TE, et al. Novel piperidine sigma receptor ligands as potential anti-psychotic drugs. J Med Chem. 1992;35:4344–4361.
   PubMed Web of Science ®Google Scholar
• Laboratorios del Dr. Esteve S.A. 1,2,4-triazole derivative as Sigma receptor inhibitors. WO2008055932; 2008
   Google Scholar
• Laboratorios del Dr. Esteve S.A. Pyrazole compounds as Sigma Receptor inhibitors. WO2011147910; 2011
   Google Scholar
• Abadias M, Escriche M, Vaqué A, et al. Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies: new sigma-1 receptor antagonist: safety, tolerability and pharmacokinetics. Br J Clin Pharmacol. 2013;75:103–117.
   PubMed Web of Science ®Google Scholar
• Vela JM, Merlos M, Almansa C. Investigational sigma-1 receptor antagonists for the treatment of pain. Expert Opin Investig Drugs. 2015;24:883–896.
   PubMed Web of Science ®Google Scholar
• Wisconsin Alumni Research Foundation. Sigma1 receptor ligands and methods of use. US8349898; 2013
   Google Scholar
• Wisconsin Alumni Research Foundation. Sigma-1 receptor ligands and methods of use. US20100179111; 2010
   Google Scholar
• Wisconsin Alumni Research Foundation. Selective Sigma-1 receptor ligands. US20130102571; 2013
   Google Scholar
• Wisconsin Alumni Research Foundation. Selective sigma-1 receptor ligands. US8946302; 2015
   Google Scholar
• E Ruoho A, Chu U, Ramachandran S, et al. The ligand binding region of the sigma-1 receptor: studies utilizing photoaffinity probes, sphingosine and N-alkylamines. Curr Pharm Des. 2012;18:920–929.
   PubMed Web of Science ®Google Scholar
• Collina S, Rossi D, Marra A, et al. Università degli Studi di Pavia. Use of arylalkanolamines as sigma-1 receptor antagonists. WO2015132733; 2015.
   Google Scholar
• Mach RH, Tu Z, Chu W, et al. Washington University. Sigma 2 receptor ligands and therapeutic uses therefor. US2008161343; 2008
   Google Scholar
• Mach RH, Tu Z, Chu W, et al. Washington University. Sigma 2 receptor ligands and therapeutic uses therefor. US7612085; 2009
   Google Scholar
• Mach RH, Hotchkiss R, Hawkins W, et al. Washington University. Therapeutic uses of bicyclic ligands of Sigma-2 receptor. US20100048614; 2010
   Google Scholar
• Mach RH, Hotchkiss R, Hawkins W, et al. Washington University. Therapeutic uses of bicylic ligands of sigma2 receptor. US8168650; 2012
   Google Scholar
• Luo S, Kansara VS, Zhu X, et al. Functional characterization of sodium-dependent multivitamin transporter in mdck-mdr1 cells and its utilization as a target for drug delivery. Mol Pharm. 2006;3:329–339.
   PubMed Web of Science ®Google Scholar
• Shi JF, Wu P, Jiang ZH, et al. Synthesis and tumour cell growth inhibitory activity of biotinylated annonaceous acetogenins. Eur J Med Chem. 2014;71:219–228.
   PubMed Web of Science ®Google Scholar
• Vadlapudi AD, Vadlapatla RK, Pal D, et al. Functional and molecular aspects of biotin uptake via SMVT in human corneal epithelial (HCEC) and retinal pigment epithelial (D407) cells. Aaps J. 2012;14:832–842.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhao X, Chen J, et al. Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjug Chem. 2010;21:979–987.
   PubMed Web of Science ®Google Scholar
• Washington University. Detection of cancer cells in vitro using S2R ligands as radiotracers. US7893266; 2011
   Google Scholar
• Adejare A Bicyclo-heptan-2-amines. US20120190710; 2012
   Google Scholar
• Washington University. Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof. WO2015153814; 2015
   Google Scholar
• Washington University. Modular platform for targeted therapeutic delivery. US20090176705; 2009
   Google Scholar
• Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369–379.
   PubMed Web of Science ®Google Scholar
• Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016;73:2195–2209.
   PubMed Web of Science ®Google Scholar
• Yagoda N, Von Rechenberg M, Zaganjor E, et al. RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447:865–869.
   Web of Science ®Google Scholar
• Gangadhar NM, Stockwell BR. Chemical genetic approaches to probing cell death. Curr Opin Chem Biol. 2007;11:83–87.
   PubMed Web of Science ®Google Scholar
• Merk Patent GMBH Use of defined substances that bind to the sigma receptor for combating sarcoma and carcinoma. WO200230422; 2002
   Google Scholar
• Vamvakides A. New sigma receptor ligands with antiapoptotic and or proapoptotic properties over cellular biochemical mechanisms, with neuroprotective, anticancer, antimetastatic and anti(chronic) inflammatory action. WO2008087458; 2008
   Google Scholar
• Vamvakides A. Tetrahydro-n,n-dimeti-iyl-2,2-diphenyl-3-feranemetiianamine, its enantiomers, and their pharmaceutically acceptable acid addition salts. WO9730983; 1997
   Google Scholar
• Vamvakides A. Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity. WO2010097641; 2010
   Google Scholar
• University of Dundee. Materials and methods relating to the induction of apoptosis in target cells. WO200000599; 2000
   Google Scholar
• Gilmore DL, Liu Y, Matsumoto RR. Review of the pharmacological and clinical profile of rimcazole. CNS Drugs Rev. 2004;10:1–22.
   Google Scholar
• De Costa BR, Bowen WD, Hellewell SB, et al. Alterations in the stereochemistry of the. kappa.-selective opioid agonist U50, 488 result in high-affinity. sigma. ligands. J Med Chem. 1989;32:1996–2002.
   PubMed Web of Science ®Google Scholar
• University of Dundee. Sigma Receptor ligands and their medical uses. WO200174359; 2001.
   Google Scholar
• Whittemore ER, Ilyin VI, Woodward RM. Antagonism of N-methyl-D-aspartate receptors by s site ligands: potency, subtype-selectivity and mechanisms of inhibition. J Pharmacol Exp Ther. 1997;282:326–338.
   Web of Science ®Google Scholar
• Appel S, Rupf A, Weck MM, et al. Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-κB and Akt signaling pathways. Clin Cancer Res. 2005;11:1928–1940.
   PubMed Web of Science ®Google Scholar
• An J, Rettig MB. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther. 2007;6:61–69.
   PubMed Web of Science ®Google Scholar
• University of Dundee. Sigma ligands and IKK/NF-kβ inhibitors for medical treatment. WO2009074809; 2009
   Google Scholar
• Patel L, Williams S, Wilding I, et al. Modern Biosciences PLC. Combination therapy comprising a taxane and a sigma receptor ligand such as rimcazole. WO2010128309; 2010
   Google Scholar
• Centre National de la Recherche Scientifique – CNRS, Paris, France/Univerite Nice Sophia Antipolis, Nice, France. Inhibitors of the interaction of the sigma-1 receptor with hERG for use in the treatment of cancer. US2015182550A1; 2015
   Google Scholar
• Renaudo A, L’Hoste S, Guizouarn H, et al. Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl- channels. J Biol Chem. 2007;282:2259–2267.
   PubMed Web of Science ®Google Scholar
• Renaudo A, Watry V, Chassot AA, et al. Inhibition of tumor cell proliferation by ligands is associated with K+ channel inhibition and p27kip1 accumulation. J Pharmacol Exp Ther. 2004;311:1105–1114.
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440:463–469.
   PubMed Web of Science ®Google Scholar
• Crottès D, Guizouarn H, Martin P, et al. The sigma-1 receptor: a regulator of cancer cell electrical plasticity? front. Physiol. 2013;4:1–10.
   Web of Science ®Google Scholar
• Happy M, Dejoie J, Zajac CK, et al. Sigma 1 receptor antagonist potentiates the anti-cancer effect of p53 by regulating ER stress, ROS production, Bax levels, and caspase-3 activation. Biochem Biophys Res Commun. 2015;456:683–688.
   PubMed Web of Science ®Google Scholar
• Schmidt HR, Zheng S, Gurpinar E, et al. Crystal structure of the human σ1 receptor. Nature. 2016;532:527–530.
   PubMed Web of Science ®Google Scholar
• Colabufo NA, Berardi F, Contino M, et al. Correlation between sigma2 receptor protein expression and histopathologic grade in human bladder cancer. Cancer Lett. 2006;237:83–88.
   PubMed Web of Science ®Google Scholar
• Cratteri P, Romanelli MN, Cruciani G, et al. GRIND-derived pharmacophore model for a series of α-tropanyl derivative ligands of the sigma-2 receptor. J Comput Aided Mol Des. 2004;18:361–374.
   PubMed Web of Science ®Google Scholar
• Abate C, Mosier PD, Berardi F et al. A Structure-Affinity and. comparative molecular field analysis of sigma-2 (sig2) receptor ligands. Cent Nerv Syst Agents Med Chem Former Curr Med Chem-Cent Nerv Syst Agents. 2009;9:246–257.
   PubMedGoogle Scholar
• Laurini E, Zampieri D, Mamolo MG, et al. A 3D-pharmacophore model for σ2 receptors based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives. Bioorg Med Chem Lett. 2010;20:2954–2957.
   PubMed Web of Science ®Google Scholar
• J Rhoades D, H Kinder D, M Mahfouz T. A comprehensive ligand based mapping of the σ2 receptor binding pocket. Med Chem. 2014;10:98–121.
   PubMed Web of Science ®Google Scholar
• Zeng C, Rothfuss JM, Zhang J, et al. Functional assays to define agonists and antagonists of the sigma-2 receptor. Anal Biochem. 2014;448:68–74.
   PubMed Web of Science ®Google Scholar
• van Waarde A, Rybczynska AA, Ramakrishnan NK, et al. Potential applications for sigma receptor ligands in cancer diagnosis and therapy. Biochim Biophys Acta BBA Biomembr. 2015;1848:2703–2714.
   PubMed Web of Science ®Google Scholar
• Kashiwagi H, McDunn JE, Simon PO, et al. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer. 2007;6:48.
   PubMed Web of Science ®Google Scholar
• Kashiwagi H, McDunn JE, Simon PO, et al. Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. J Transl Med. 2009;7:24.
   PubMed Web of Science ®Google Scholar
• Mach RH, Zeng C, Hawkins WG. The σ 2 receptor: a novel protein for the imaging and treatment of cancer. J Med Chem. 2013;56:7137–7160.
   PubMed Web of Science ®Google Scholar
• Ohman KA, Hashim YM, Vangveravong S, et al. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Oncotarget. 2016;7:33529–33541.
   PubMed Web of Science ®Google Scholar
• Marrazzo A, Fiorito J, Zappalà L, et al. Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells. Eur J Med Chem. 2011;46:433–438.
   PubMed Web of Science ®Google Scholar
• Meunier B. Hybrid molecules with a dual mode of action: dream or reality? Acc. Chem Res. 2008;41:69–77.
   PubMed Web of Science ®Google Scholar
• Shoghi KI, Xu J, Su Y, et al. Quantitative receptor-based imaging of tumor proliferation with the sigma-2 ligand [18F]ISO-1. Plos ONE. 2013;8:e74188.
   Google Scholar
• Dehdashti F, Laforest R, Gao F, et al. Assessment of cellular proliferation in tumors by PET using 18F-ISO-1. J Nucl Med. 2013;54:350–357.
   PubMed Web of Science ®Google Scholar
• Abramson Cancer Center of University of Pennsylvania. Imaging of in vivo sigma-2 receptor expression with [18F]ISO-1 positron emission tomography (PET/CT) in primary breast cancer. 2016. Available from: https://clinicaltrials.gov/show/NCT02762110
   Google Scholar